Published 18 December 2008, doi:10.1136/bmj.a3061
Cite this as: BMJ 2008;337:a3061

News

Researchers refine in vitro test that will reduce the risk of "first in humans" drug trials

Susan Mayor

1 London

The first 150 words of the full text of this article appear below.

UK researchers investigating what went wrong in the drug trial with the immunomodulator TGN1412 in 2006, in which six healthy volunteers became critically ill, have developed an in vitro test that could have predicted the drug’s serious side effects before it was tested in humans.

The six men had catastrophic multiorgan failure when they took part in a "first in humans" trial of TGN1412—a monoclonal superagonist of the CD28 T cell surface receptor, which was being tested for use in autoimmune conditions. The drug triggered a systemic inflammatory response with rapid induction of proinflammatory cytokines; this caused a life threatening "cytokine storm," which had not been predicted from preclinical testing (BMJ 2006;333:570; 10.1136/bmj.333.7568.570).

The UK Medicine and Healthcare Products Regulatory Agency (MHRA) commissioned the government funded National Institute for Biological Standards and Control (NIBSC) to investigate why in vitro human cell tests and in vivo animal tests failed . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

In the eye of the storm
Susan Mayor
BMJ 2006 333: 570. [Extract] [Full Text] [PDF]

Access jobs at BMJ Careers
Whats new online at Student BMJ